Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program.
Saved in:
| Title: | Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program. |
|---|---|
| Authors: | O'Hagan A; Johnson & Johnson, Spring House, PA, 19477, United States., Siefker-Radtke A; The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States., Loriot Y; Institut Gustave Roussy, Villejuif, 94805, France., Deprince K; Johnson & Johnson, Beerse, 2340, Belgium., Crow L; Johnson & Johnson, Spring House, PA, 19477, United States., Laron M; Johnson & Johnson, Milpitas, CA, 95054, United States., Adelman R; Mayo Clinic, Jacksonville, FL, 32224, United States., Sweiti H; Johnson & Johnson, Spring House, PA, 19477, United States., Triantos S; Johnson & Johnson, Spring House, PA, 19477, United States. |
| Source: | The oncologist [Oncologist] 2026 Jun 06; Vol. 31 (7). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyag174 |
